PALO ALTO, Calif. – August 5, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in August.
- BTIG Biotechnology Conference at St. Regis Hotel in New York City. Eiger will host one-on-one meetings.
- 2019 Wedbush PacGrow Healthcare Conference at Parker New York Hotel in New York City. Eiger will present a corporate update with a live webcast on August 13, 3:05-3:35 PM ET. Eiger will host one-on-one meetings.
The live webcast of the Wedbush presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the “Investors” tab. A replay of the webcast will be available approximately one hour following the live event.
Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of a pipeline of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs and for which no approved therapies exist.
The Company’s lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection. The company is also advancing peginterferon lambda, a first-in-class interferon, toward a Phase 3 study for the treatment of HDV. Eiger is preparing an NDA and MAA for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies with plans to file in 2019. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
SOURCE Eiger BioPharmaceuticals, Inc.
Investors: Ingrid Choong, PhD